Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients

BACKGROUND: Secondary hyperparathyroidism (SHPT) is one of the major risk factors of morbidity and mortality in end-stage renal disease. Cinacalcet effectively controls SHPT without causing hypercalcemia and hyperphosphatemia. However, there is significant inter-individual response variance to cinac...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Drug Des Devel Ther
Autori principali: Jeong, Sohyun, Kim, In-Wha, Oh, Kook-Hwan, Han, Nayoung, Joo, Kwon Wook, Kim, Hyo Jin, Oh, Jung Mi
Natura: Artigo
Lingua:Inglês
Pubblicazione: Dove Medical Press 2016
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4944925/
https://ncbi.nlm.nih.gov/pubmed/27468225
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S103370
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi